Progress of research on respiratory syncytial virus vaccine for children
10.3760/cma.j.cn101070-20240808-00502
- VernacularTitle:儿童呼吸道合胞病毒疫苗的研究进展
- Author:
Xiaolei GUO
1
;
Feng LIU
1
;
Deyu ZHAO
1
Author Information
1. 南京医科大学附属儿童医院呼吸科，南京 210008
- Publication Type:Journal Article
- Keywords:
Child;
Respiratory syncytial virus;
Vaccine
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(6):465-468
- CountryChina
- Language:Chinese
-
Abstract:
Respiratory syncytial virus (RSV) is one of the most important pathogens causing respiratory infections in children, and a major cause of hospitalization and death.However, current therapeutic measures are based on supportive care and there is a lack of specific antiviral drugs, so prevention of RSV infection is extremely important.Active and passive immunization is the main way to prevent infection, but monoclonal antibodies are not widely applied in clinical practice because they are high-priced and some of them need multiple doses.Therefore, it is important to develop a usable RSV vaccine.Progress of vaccine research was slow previously due to the vaccine-enhanced disease caused by Formalin-inactivated vaccines and the difficult pre-preparation and poor stability of attenuated vaccines.With the gradual clarification of the structural characteristics of RSV fusion proteins, the maturation of biotechnology, and the emergence of component vaccines recently, vaccine research and development has made great progress, and the maternal vaccine Abrysvo has now been approved for the prevention of RSV infections in infants and young children.This review provides an overview of the biological structure of RSV and the current status of research on pediatric RSV vaccine.
